Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The efficacy of cevostamab in R/R multiple myeloma and the importance of bispecific antibodies

Amrita Krishnan, MD, City of Hope, Duarte, CA, gives an overview of the safety and efficacy of cevostamab in patients with relapsed/refractory (R/R) multiple myeloma, and further highlights the importance of bispecific antibodies in this disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.